Bayer Aktiengesellschaft (ETR:BAYN)
33.31
-0.27 (-0.80%)
At close: Dec 5, 2025
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 9.66B EUR in the quarter ending September 30, 2025, a decrease of -3.09%. This brings the company's revenue in the last twelve months to 45.87B, down -1.87% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
45.87B
Revenue Growth
-1.87%
P/S Ratio
0.71
Revenue / Employee
518.25K
Employees
91,864
Market Cap
32.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.27B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Sartorius Aktiengesellschaft | 3.52B |
| Fresenius Medical Care AG | 19.64B |
| Carl Zeiss Meditec AG | 2.18B |
| Fielmann Group AG | 2.42B |
| SCHOTT Pharma AG & Co. KGaA | 975.68M |
Bayer Aktiengesellschaft News
- 1 day ago - EQS-News: Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis - Wallstreet:Online
- 2 days ago - EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 2 days ago - Evotec & Bayer Launch Phase 2 Trial for Alport Syndrome Treatment - Wallstreet:Online
- 2 days ago - EQS-News: Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome - Wallstreet:Online
- 2 days ago - Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome - Business Wire
- 2 days ago - RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints - Wallstreet:Online
- 2 days ago - RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints - Business Wire
- 2 days ago - Bayer (BAYRY) Achieves Milestone with Pediatric MRI Contrast Agent Study - GuruFocus